For each included study, the following data items were collected: author(s), year of publication, country of study, study design, patient demographics (e.g., age, sex), indication for GLP-1 RA use (e.g., T2DM, obesity), specific GLP-1 agonist administered (e.g., semaglutide), and key outcomes (Table 1). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.